Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc.INDV · Entity 4040 | Director | May 13, 2026 | May 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Indivior Pharmaceuticals, Inc.
Report date May 13, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,042 |
Reported balance
After 2026-05-13 transaction · row 1
1 source rowRow 1 · 2026-05-13 · Grant · Acquired 6,518 · Balance 16,042 F1: Reflects a grant of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the day immediately preceding the date of the annual meeting of the Issuer's stockholders following the date of grant, subject to the Reporting Person's continued service to the Issuer on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a grant of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the day immediately preceding the date of the annual meeting of the Issuer's stockholders following the date of grant, subject to the Reporting Person's continued service to the Issuer on the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 13, 2026 Filed May 14, 2026 20:11 UTC | Indivior Pharmaceuticals, Inc. INDV · Entity 4040 | GrantCommon Stock | 6,518 | $0.00 | $0.00 |
DisclosureSEC source: 0002014900-26-000009 · wk-form4_1778789470.xml · nonDerivative · entry 1 Humphreys Keith · CIK 0002014900 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,042 F1 · shares: Reflects a grant of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the day immediately preceding the date of the annual meeting of the Issuer's stockholders following the date of grant, subject to the Reporting Person's continued service to the Issuer on the vesting date. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 21:05 UTC | Indivior Pharmaceuticals, Inc. INDV · Entity 4040 | GrantCommon Stock | 3,722 | $0.00 | $0.00 |
DisclosureSEC source: 0002014900-26-000006 · wk-form4_1769634350.xml · nonDerivative · entry 1 Humphreys Keith · CIK 0002014900 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,524 F1 · shares: Reflects a grant of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the day immediately preceding the date of the first annual meeting of the Issuer's stockholders following the date of grant, subject to the Reporting Person's continued service to the Issuer on the vesting date. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 18:50 UTC | Indivior Pharmaceuticals, Inc. INDV · Entity 4040 | PurchaseOrdinary Shares | 775 | $35.39 | $27,429.27 |
DisclosureSEC source: 0002014900-26-000004 · wk-form4_1767811835.xml · nonDerivative · entry 1 Humphreys Keith · CIK 0002014900 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,802 F1 · kind: Securities acquired pursuant to the director's participation in a Non-Executive Director Purchase Plan to receive a portion of the fees received for service as a director in stock in lieu of cash. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.